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Purpose: Low molecular weight iron(III) complex-based contrast agents (IBCA) 
including iron(III) trans-cyclohexane diamine tetraacetic acid [Fe(tCDTA)]− could 
serve as alternatives to gadolinium-based contrast agents in MRI. In search for IBCA 
with enhanced properties, we synthesized derivatives of [Fe(tCDTA)]− and com-
pared their contrast effects.
Methods: Trans-cyclohexane diamine tetraacetic acid (tCDTA) was chemi-
cally modified in 2 steps: first the monoanhydride of Trans-cyclohexane diamine 
tetraacetic acid was generated, and then it was coupled to amines in the second step. 
After purification, the chelators were analyzed by high-performance liquid chro-
matography, mass spectrometry, and NMR spectrometry. The chelators were com-
plexed with iron(III), and the relaxivities of the complexes were measured at 0.94, 
1.5, 3, and 7 Tesla. Kinetic stabilities of the complexes were analyzed spectrophoto-
metrically and the redox properties by cyclic voltammetry.
Results: Using ethylenediamine (en) and trans-1,4-diaminocyclohexane, we 
generated monomers and dimers of tCDTA: en-tCDTA, en-tCDTA-dimer, 
trans-1,4-diaminocyclohexane-tCDTA, and trans-1,4-diaminocyclohexane-tCDTA-
dimer. The iron(III) complexes of these derivatives had similarly high stabilities as 
[Fe(tCDTA)]−. The iron(III) complexes of the trans-1,4-diaminocyclohexane deriv-
atives had higher T1 relaxivities than [Fe(tCDTA)]
− that increased with increasing 
magnetic field strengths and were highest at 6.8 L·mmol−1·s−1 per molecule for the 
dimer. Remarkably, the relaxivity of [Fe(en-tCDTA)]+ had a threefold increase from 
neutral pH toward pH6.
Conclusion: Four iron(III) complexes with similar stability in comparison to 
[Fe(tCDTA)]− were synthesized. The relaxivities of trans-1,4-diaminocyclohexane-
tCDTA and trans-1,4-diaminocyclohexane-tCDTA-dimer complexes were in the 
same range as gadolinium-based contrast agents at 3 Tesla. The [Fe(en-tCDTA)]+ 
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1 |  INTRODUCTION
The occurrence of nephrogenic systemic fibrosis in patients 
with disturbed kidney function1 but especially the deposition of 
gadolinium originating from linear and macrocyclic gadolini-
um-based contrast agents (GBCA) in several organs, including, 
skin, bones, and brain,2-5 in patients with normal kidney func-
tion resulted in the suspension of less stable linear GBCA, with 
the exception of 2 liver-targeted GBCA (gadoxetic acid and 
gadobenic acid), by the European Medicines Agency in 2017. 
Furthermore, there is an ongoing controversy about what has 
been termed gadolinium deposition disease.6 Although apart 
from the bones the brain appears to accumulate substantial Gd, 
it appears not to be the most severely affected organ because 
even a patient who died of nephrogenic systemic fibrosis had 
no obvious brain tissue alterations.4 Thus, other organs and 
cells, especially of the immune system, should be investigated 
for evidence of potential gadolinium side effects in the future. 
This situation, along with the low but increasing contamination 
of rivers and drinking water by gadolinium,7-10 has motivated 
us to investigate low molecular weight iron(III) complexes as 
iron-based contrast agents (IBCA) for use in MRI, although the 
more stable macrocyclic GBCA are continued to be considered 
as safe drugs.
Recently, we have demonstrated that IBCA administered 
at higher doses than GBCA achieved similar results in typical 
clinical applications such as dynamic contrast-enhanced MRI 
and magnetic MRA without the need to modify imaging pro-
tocols.11 Especially the iron(III) complex of trans-cyclohexane 
diamine tetraacetic acid ([Fe(tCDTA)]−) provided compara-
ble contrast effects at only twice the typical clinical dose of 
Magnevist (Bayer AG, Pharmaceuticals, Berlin, Germany, 
gadolinium diethylenetriaminepentaacetic acid). The relatively 
strong contrast effect in comparison to [Fe(DTPA)]2− might 
be attributed to the availability of a water coordination site in 
[Fe(tCDTA)]−.11,12 Since then, an iron(II) complex of PyC3A, 
which served as a redox sensor through oxidation of low relax-
ivity Fe2+ to high relaxivity Fe3+,13 and a group of macrocyclic 
iron complexes with good relaxivities and relatively long per-
sistence in liver and kidneys have been reported.14,15
The purpose of this work was to produce several tCDTA de-
rivatives by coupling amine-containing compounds to 1 carboxyl 
group of tCDTA and to thus obtain compounds with improved 
or modified contrast agent properties (Figure 1). The amines we 
tested were ethylenediamine and trans-1,4-diaminocyclohexane 
to generate tCDTA monomers that can serve for chemical cou-
pling purposes and to generate tCDTA dimers for reduced rota-
tional times and thus potentially increased relaxivities.14,16
2 |  METHODS
2.1 | Reagents
If not specified otherwise, all reagents were purchased from 
Merck KGaA (Darmstadt, Germany).
2.2 | Synthesis of trans-1,2-
diaminocyclohexane-N,N,N′,N′-tetraacetic acid 
monoanhydride (tCDTA-MA)
6.53 g (17.9 mmol) of trans-1,2-diaminocyclohexane-
N,N,N′,N′-tetraacetic acid (tCDTA) (Carl Roth GmbH, 
Karlsruhe, Germany) was added to a solution of 12.87 
mL (136.2 mmol) acetic anhydride and 2.75 mL pyridine 
(34.0  mmol). After stirring for 24 h at room temperature 
under an argon atmosphere, the reaction mixture was filtered 
and washed with acetic anhydride followed by excess ethyl 
acetate. The solid was collected and dried under vacuum to 
give 5.30 g (81.2%) of the white powder tCDTA-MA.17
2.3 | Synthesis of chelators
2.3.1 | Synthesis of ethylenediamine-tCDTA 
monomer (en-tCDTA)
tCDTA-MA (14.4 mmol, 5 g) was added in small portions as 
solid over a period of 6 h to a solution of 19.31 mL ethylen-
ediamine (289 mmol) and 23.75 mL dimethyl sulfoxide under 
an argon atmosphere. After addition, the reaction mixture was 
stirred overnight at room temperature. The mixture was then 
concentrated under reduced pressure (8 mbar) to a thick orange 
oil that solidified upon standing. The residue was dissolved in 
methanol and formed a precipitate at room temperature, which 
was washed several times with methanol to give 3.98 g (80%) 
of a white solid. Matrix-assisted laser desorption/ionization 
complex is a pH sensor at weakly acidic pH levels, which are typical for various 
cancer types.
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(MALDI) mass spectrometry measurements (MALDI-TOF/
TOF 4700 Proteomics Analyzer, Applied Biosystems, Foster 
City, USA) gave an expected/measured mass of 389.42/389.18 
[M+H]+ (see Supporting Information Figure S2 and S4)—1H-
NMR (400 MHz, D2O): 3.57 (s, 3H), 3.53 (s, 3H), 3.48 (s, 1H), 
3.44 (s, 1H), 3.03 (t, 2H), 2.92 (m, 4H), 2.16 (m, 2H), 1.82 (m, 
2H), 1.26 (m, 4H); 13C-NMR (D2O): 170.88, 60.26, 50.86, 
39.58, 24.17, 23.29; C,H,N-analysis [%]: C 43.94, H 8.12, N 
15.07; calculated for C16H27N4O7(NH4) × 2 H2O: C 43.98, H 
7.84, N 15.23; maximum deviation: 0.28.
2.3.2 | Synthesis of ethylenediamine-tCDTA 
dimer (en-Di-tCDTA)
tCDTA-MA (13.5  mmol, 4.66  g) was added in small por-
tions as solid over a period of 6  h to a solution of 0.45  mL 
ethylenediamine (6.7  mmol), 22.15  mL dimethyl sulfoxide, 
and 4.36 mL (53.9 mmol) pyridine under argon atmosphere. 
After addition, the reaction mixture was stirred overnight at 
room temperature. This mixture was further washed with excess 
ethanol and then purified by semipreparative high-performance 
liquid chromatography (HPLC) (5 mM ammonium bicarbonate 
buffer with pH 7.78, 2% to 66% acetonitrile gradient over 20 
min). The fractions containing en-Di-tCDTA were identified by 
HPLC and lyophilized. MALDI mass spectrometry measure-
ments (MALDI-TOF/TOF 4700 Proteomics Analyzer, Applied 
Biosystems) gave an expected/measured mass of 717.74/699.11 
[M+H]+ −18 (dehydration; see Results section and Supporting 
Information Figure S2 and S4)—1H-NMR (400 MHz, D2O): 
3.65-3.85 (16H), 3.35 (m, 4H), 3.08 (m, 4H), 2.17 (m, 4H), 1.84 
(m, 4H), 1.29 (m, 8H)); C,H,N-analysis [%]: C 46.72, H 7.02, N 
10.96; calculated for C30H47N6O14Na × 2.15 H2O: C 46.35, 
H 6.65, N 10.81; maximum deviation: 0.37.
F I G U R E  1  Synthesis of tCDTA chelator derivatives. (A) First, tCDTA-monoanhydride (tCDTA-MA) was generated by reaction of tCDTA 
with acetic anhydride and pyridine followed by purification to remove dianhydrides by filtration with acetic anhydride. In the second step, tCDTA-
MA reacted with amine-containing compounds to give 4 different carboxamide derivatives of tCDTA that are shown as chemical structures and 
corresponding putative molecular models in (B-E). Following the procedure in (A), the reaction of tCDTA-MA with ethylenediamine (flexible) in 
molar excess resulted in the monomer ethylenediamine-tCDTA (B), whereas reaction of ethylenediamine with half-molar (or less) ratio to tCDTA-
MA gave the dimer ethylenediamine-Di-tCDTA (C). The reaction of trans-1,4-diaminocyclohexane (rigid) in molar excess to tCDTA-MA resulted 
in the monomer trans-1,4-diaminocyclohexane-tCDTA (D), whereas reaction of trans-1,4-diaminocyclohexane in half-molar ratio to tCDTA-MA 
gave the dimer trans-1,4-diaminocyclohexane-Di-tCDTA (E). tCDTA, trans-cyclohexane diamine tetraacetic acid; tCDTA-MA, trans-cyclohexane 
diamine tetraacetic acid–monoanhydride
(A)
(B) (C) (D) (E)
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2.3.3 | Synthesis of trans-1,4-
diaminocyclohexane-tCDTA monomer   
(trans-tCDTA)
tCDTA-MA (6.93 mmol, 2.4 g) was added in small portions as 
solid over a period of 6 h to a solution of 3.17 g trans-1,4-diami-
noclyclohexane (27.7 mmol) dissolved in 18.24 mL dimethyl 
sulfoxide under argon atmosphere at approximately 90°C and 
stirred for another 4 h. The reaction mixture was stirred over-
night at room temperature. The mixture was then concentrated 
under reduced pressure (8 mbar) to an ashen solid. After dissolv-
ing in methanol, a precipitate formed at room temperature within 
2 days. The precipitate was washed several times with methanol 
to give 1.89 g (79%) of a white solid. MALDI mass spectrometry 
measurements (MALDI-TOF/TOF 4700 Proteomics Analyzer, 
Applied Biosystems) gave an expected/measured mass of 
443.51/443.26 [M+H]+ (Supporting Information Figure S2 and 
S4)—1H-NMR (400 MHz, D2O): 3.55 (m, 8H), 2.93 (m, 2H), 
2.16 (m, 2H), 2.07 (m, 2H), 1.83 (m, 2H), 1.50 (m, 8H), 1.25 
(m, 4H); 13C-NMR (D2O): 172.94, 170.24, 63.16, 60.10, 54.75, 
49.08, 48.41, 29.11, 27.98, 24.12, 24.04; C,H,N-analysis [%]: C 
51.09, H 8.3, N 13.19; calculated for C20H34N4O7 × 0.5 NH3 × 
1.15 H2O: C 50.92, H 8.08, N 13.36; max. deviation: 0.22).
2.3.4 | Synthesis of trans-1,4-
diaminocyclohexane-tCDTA dimer (trans-  
Di-tCDTA)
tCDTA-MA (17.9 mmol, 5.16 g) was added over 6 h as above to 
a solution of trans-1,4-diaminocyclohexane (7.4 mmol, 0.85 g) 
in 4.82 mL (59.6 mmol) pyridine and 58.80 mL dimethyl sul-
foxide. The reaction mixture was stirred overnight under argon 
atmosphere at room temperature. The mixture was dried in a 
rotary evaporator to give a whitish solid. The resulting residue 
was washed and filtrated with ethanol; the filtrate was collected 
and then lyophilized to provide a white powder. The MALDI 
mass spectrometry measurements (Mikroflex MALDI mass 
spectrometer, Bruker Daltonics, Bremen, Germany) gave an 
expected/measured mass of 771.83/771.18 [M+H]+ (see 
Supporting Information Figure S2 and S4)—1H-NMR (400 
MHz, D2O): 3.36 (m, 4H), 3.13 (m, 12H), 2.95 (m, 4H), 2.32 
(m, 4H), 1.94 (m, 4H), 1.87 (m, 2H), 1.68 (m, 8H), 1.30 (m, 
8H); 13C-NMR (D2O): 172.68, 60.34, 52.57, 47.73, 38.77, 
25.12, 23.47; C,H,N-analysis [%]: C 47.62, H 7.15, N 9.01; cal-
culated for C34H55N6O14(HCO3) × 3.2 H2O: C 47.21, H 7.06, N 
9.44; maximum deviation: 0.43.
2.4 | Synthesis of iron(III) complexes
Iron(III) complexes were prepared by reaction of the tCDTA 
chelators (see above) with a stoichiometric equivalent of 
FeCl3 solution (1 M, adjusted with a commercial iron chlo-
ride calibration solution, final concentrations of 20 to 50 mM) 
to the binding centers (1:1 ratio for monomers and 2:1 ratio 
for dimers). Next, the solution was adjusted slowly with a 
saturated meglumine solution to pH 7.4. After 1 day, the iron 
complex solutions were centrifuged at 13,800 g for 20 min 
to remove any excess iron in the form of insoluble iron(III) 
hydroxide (solubility product 2.8 × 10−39 at 25°C), and the 
supernatant was filtered with 0.45 µm syringe filters.
2.5 | HPLC analysis
New compounds were assessed after synthesis and purification 
by reverse-phase HPLC on a Dionex UltiMate 3000 system 
(Thermo Fisher Scientific, Waltham, USA). The conditions 
and results are given in the Supplementary Information sec-
tion Figure S1. Sample detection was performed by absorption 
measurement at 210 nm using a diode array detector (Dionex 
UltiMate 3000, Thermo Fisher Scientific, Waltham, USA).
2.6 | Mass spectrometry 
analysis of chelators
After purification and analysis of the purity by HPLC, the 
tCDTA derivatives were analyzed by MALDI-TOF mass 
spectrometry in the reflector mode on instruments 4700 
Proteomics Analyzer (Applied Biosystems, Foster City, USA) 
and Microflex LRF (Bruker Daltonics, Bremen, Germany). 
Measurements were performed by the Shared Facility 
of Mass Spectrometry of the Institute of Biochemistry, 
Charité—Universitätsmedizin Berlin. Mass spectrometry re-
sults are presented in the Supporting Information Figure S2.
2.7 | Infrared spectroscopy
Infrared spectroscopy spectra of lyophilized substances 
were recorded on a Bruker Compact FT- infrared spectros-
copy spectrometer ALPHA-P using the OPUS software 
(OPUS 6.5, Bruker Optik GmbH, Germany). See Supporting 
Information Figure S3.
2.8 | NMR
NMR of the chelators spectra were recorded on a Bruker AV 400 
NMR spectrometer (1H and 13C 400 MHz) in D2O at room tem-
perature. Chemical shifts are reported in ppm relative to residual 
proton signals of D2O (4.8 ppm). For NMR spectrometry of 
trans-Di-tCDTA, the sodium salt was used due to the low solubil-
ity of the free acid. See also Supporting Information Figure S4.
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2.9 | Stability measurement
Stability of the iron complexes (1.0 mM Fe) was compared 
by measuring the changes in absorption spectra between 220 
and 500 nm over time during treatment with 100 mM HCl 
according to Snyder et al.14 Additionally, we compared the 
absorption spectra to those of FeCl3 in 100 mM HCl and 
tCDTA in 100 mM HCl, and [Fe(tCDTA)]− in 1 M HCl.
2.10 | Cyclic voltammetry
Electrochemical studies were carried out using a EmStat Blue 
potentiostat (PalmSens BV, Houten, The Netherlands) in a con-
ventional 1-compartment 3-electrode cell with a glassy carbon 
electrode (ID 1.6 mm) as the working electrode, a platinum plate 
(5 × 5 mm) as the counter electrode, and a silver wire in aqueous 
AgCl solution as the pseudo-reference electrode. All measure-
ments were carried out in deionized and degassed H2O solutions 
containing 0.1 M KCl at pH 5.9 under argon atmosphere at am-
bient temperature. Cyclic voltammograms were collected at a 
scan rate of 0.1 Vs−1. See also Supporting Information Table S1.
2.11 | Relaxivity measurement by 
relaxometry
For relaxivity measurements, all iron complexes were diluted 
in water or fetal calf serum (FCS) (Gibco, Thermo Fisher 
Scientific, Rockford, IL) at concentrations of 0.125, 0.25, 
0.5, and 1.0 mM at pH 7.4 and loaded into glass NMR tubes 
(5 mm outside diameter; Wilmad-Lab Glass, Vineland, USA). 
Measurements at 0.94 Tesla (T) were performed using an NMR 
relaxometer Minispec mq 40 (Bruker BioSpin, Rheinstetten, 
Germany) according to the manufacturer’s instructions. For 
measurements of the pH dependence, samples of [Fe(en-
tCDTA)]+ in the concentrations above were dissolved in water 
or FCS and adjusted to the different pH values.
2.12 | Relaxivity measurement by 
MR imaging
Relaxivities at 1.5 T, 3 T, and 7 T were measured on MRI 
scanners. Up to 7 samples prepared as above were placed in 
a circular phantom holder at room temperature. For measure-
ments at 37°C, a phantom holder equipped with water heat-
ing was kept at 37°C ± 1°C and monitored by a fiber optic 
temperature probe. Measurements at 1.5 T were conducted 
on a Magnetom Sonata (Siemens, Erlangen, Germany) and at 
3 T on a Magnetom Lumina (Siemens) clinical MRI scanner 
using standard 2D spin echo sequences. Different repetition 
times (TR) of 100, 150, 300, 600, and 1000 ms were used 
to measure T1 times and calculate T1 relaxivities. Echo time 
(TE) was 11 ms for 1.5 T and 13 ms for 3 T. Other imaging 
parameters were matrix of 256 × 256, field of view (FOV) 
of 75 × 75 mm2, and the slice thickness of 5 mm. The T1 
maps were generated from the resulting image datasets using 
ImageJ with the MRI Analysis Calculator plug-in from Karl 
Schmidt (v1.0, kfschmidt@bwh.harvard.edu, 2002/06/19).
For measurement at 7 T, the phantoms were imaged on 
a BioSpec small animal MRI scanner (Bruker, Ettlingen, 
Germany) using a built-in dedicated multi-TR spin echo se-
quence with integrated T1 mapping. The TRs were 25, 72, 
125, 186, 258, 346, 459, 617, 882, and 2000 ms. TE was 9.0 
ms; an imaging matrix of 256 × 256 was used with a FOV 
50 × 50 mm2 and slice thickness 1 mm.
T1 times of the samples determined by MRI were mea-
sured in circular regions of interest of constant size placed in 
the center of the cross sections of each tube in the T1 maps.
The T1 and T2 relaxivities were determined by performing 
linear regression analysis of 1/T versus iron concentration of 
the complexes using GraphPad Prism version 5.0a (GraphPad 
Software, Inc., San Diego, CA).
2.13 | Molecular modeling
Molecular modeling of the complexes was done based on 
the X-ray crystal structures of [Fe(tCDTA)]−12 using Marvin 
software followed by Dreiding force field energy minimiza-
tion (Marvin version 19.17, 2019, ChemAxon, Budapest, 
Hungary) and the PyMOL Molecular Graphics System 
(Schrödinger, Inc, New York, USA, Open Source version 
1.8.2.1., on Apple XQuartz 2.7.11 X Window System).18
3 |  RESULTS
In this study, we synthesized tCDTA derivatives in 2 steps 
as shown in Figure 1A using a method adapted from Gestin 
et al.17 First, a monoanhydride of tCDTA (tCDTA-MA) was 
generated using acetic anhydride in the presence of pyridine 
as proton acceptor. After separation from dianhydrides by fil-
tration, tCDTA-MA was reacted either with an excess of the 
diamine compounds to generate monomers (defined as the 1:1 
condensation reaction product) or with less than half-molar 
amounts of diamines to synthesize dimers (defined as the 2:1 
condensation reaction product). In this way, the reaction with 
ethylenediamine resulted in the monomer ethylenediamine-
tCDTA (en-tCDTA) (Figure 1B, MW 388.42) and the dimer 
ethylenediamine-Di-tCDTA (en-Di-tCDTA) (Figure 1C, MW 
716.74). Accordingly, reacting tCDTA-MA with an excess of 
trans-1,4-diaminocyclohexane gave the monomer trans-1,4-
diaminocyclohexane-tCDTA (trans-tCDTA) (Figure 1D, 
MW 442.51), whereas reaction with a half-molar amount of 
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trans-1,4-diaminocyclohexane resulted in the dimer trans-1,4-
diaminocyclohexane-Di-tCDTA (trans-Di-tCDTA) (Figure 1E, 
MW 770.83). HPLC analysis (see Supporting Information 
Figure S1) of purified amides yielded purities with the follow-
ing peak area percentages—en-tCDTA: 98.1%; en-Di-tCDTA: 
96.6%; trans-tCDTA: 99.0%; and trans-Di-tCDTA: 98.4%. 
Absence of relevant amounts of tCDTA was confirmed by 
HPLC for all chelators, which is an important precondition for 
relaxivity measurements excluding contributions from the cor-
responding iron complexes. Product identities were confirmed 
by MALDI mass spectrometry, 1H and 13C NMR, and elemen-
tal analysis (see Supporting Information Figure S4). The main 
mass peaks of en-Di-tCDTA (and to a very small extent, also 
those of en-tCDTA) were reduced by 18 Da, which can be at-
tributed to dehydration during the MALDI mass spectrometry.19 
For confirmation, we compared the infrared spectroscopy spec-
tra of tCDTA, tCDTA-MA, en-tCDTA, and en-Di-tCDTA by 
infrared spectroscopy (see Supporting Information Figure S3). 
As expected, we found the characteristic bands for anhydrides 
only for tCDTA-MA.
After preparation of the iron(III) complex solutions by 
letting react the chelators with iron(III) chloride, we com-
pared the stabilities of the new iron complexes with that of 
[Fe(tCDTA)]−, which was reported to have a rather high com-
plex stability constant, log K, of 27.520 or of 29.3.21 Figure 2  
(and Supporting Information Figure S5) shows the absorp-
tion spectra of the iron(III) complexes over time during a 
challenge with 100 mM HCl, as done by Snyder et al.14 All 
tested complexes revealed only minimal initial absorbance 
changes at 100 mM HCl and thus differed from iron(III) chlo-
ride at 100 mM HCl and to [Fe(tCDTA)]− at 1 M HCl.
Redox properties of the iron(III) complexes were exam-
ined by cyclic voltammetry using a glassy carbon working 
electrode and KCl as a supporting electrolyte. The peak po-
tential values obtained for the oxidation/reduction events are 
compiled (referenced to an Ag/AgCl electrode) in Supporting 
F I G U R E  2  Comparison of stabilities of the iron(III) complexes of tCDTA and the new derivatives over time. The dissociation of [Fe(tCDTA)]− 
(A), [Fe(en-tCDTA)]+ (B), [Fe(trans-tCDTA)]+ (C), and [Fe(trans-Di-tCDTA)] (D) was monitored by measuring absorption spectra (1.0 mM Fe) over 
time in 100 mM HCl and observing the reduction of absorbance at 300 nm according to Snyder et al.14 (E) Free FeCl3 has an absorption minimum at 
300 nm, and tCDTA has only minimal absorption below 250 nm (both in 100 mM HCl). In comparison to harsh treatment with 1 M HCl, which caused 
a time-dependent dissociation of [Fe(tCDTA)]− (F), all [Fe(tCDTA)]− derivatives were remarkably stable at 100 mM HCl. [Fe(tCDTA)]−, iron(III) 
complex of trans-cyclohexane diamine tetraacetic acid; [Fe(en-tCDTA)]+, iron(III) complex of ethylenediamine-tCDTA; [Fe(trans-tCDTA)]+, iron(III) 
complex of trans-1,4-diaminocyclohexane-tCDTA; [Fe(trans-Di-tCDTA)], iron(III) complex of trans-1,4-diaminocyclohexane-Di-tCDTA
(A) (C)(B)
(D) (F)(E)
F I G U R E  3  Cyclic voltammetry of iron complexes at neutral pH 
and a scan rate of 100 mV/s. Solutions contained 1.0 mM of the iron 
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Information Table S1. The cyclic voltammograms of all 3 
complexes (Figure 3) exhibited 1 reversible redox wave in 
the anodic scan (Ea ≈ +0.06 V for [Fe(tCDTA)]
− and around 
+0.1 V for the other complexes). Whereas reversible ca-
thodic waves were observed for [Fe(tCDTA)]− and [Fe(trans-
tCDTA)]+, the other 2 complexes showed 2 small cathodic 
peak potentials, indicating the presence of 2 different spe-
cies. Half-wave potentials E1/2 in the range of −0.05 to 0.06 V 
were calculated (Supporting Information Table S1).
Relaxivity, an important measure for the contrast effect, 
was analyzed at different field strengths (Table 1). The iron 
complexes of the chelators en-tCDTA (Figure 1B) and en- 
Di-tCDTA (Figure 1C), which were generated with ethylene-
diamine, had relatively low relaxivities at 0.94 T and neutral 
pH, whereas trans-tCDTA (Figure 1D) and trans-Di-tCDTA 
(Figure 1E) had relaxivities comparable to tCDTA at this 
field strength. However, at higher field strengths the T1 re-
laxivities increased substantially and were highest at 7 T for 
the dimer trans-Di-tCDTA (Figure 1E), namely 4.71 ± 0.37 
L·mmol−1·s−1 per iron and 9.42 ± 0.74 mM−1s−1 per dimeric 
molecule in water and 3.23 ± 0.35 L·mmol−1·s−1/6.46 ± 0.70 
L·mmol−1·s−1 in serum (Table 1). Figure 4 demonstrates 
the contrast effects in MR phantom images of trans-tCDTA 
(Figure 4A,B) and trans-Di-tCDTA (Figure 4C,D) at differ-
ent concentrations and neutral pH in water and in serum.
The surprisingly low relaxivities of [Fe(en-tCDTA)]+ and 
[Fe(en-Di-tCDTA)] compared with [Fe(trans-tCDTA)]+ and 
[Fe(trans-Di-tCDTA)] at neutral pH could be explained by 
the coordination of the distant amine groups to the chelated 
iron or alternatively by hydroxide ion coordination (Figure 5). 
Accordingly, the relaxivities of [Fe(en-tCDTA)]+ (Figures 6 
and 7) and to a lesser extent of [Fe(en-Di-tCDTA)] (Supporting 
Information Figure S7) determined by relaxometry at 0.94 T in-
creased substantially as the pH was lowered. In water (Figure 6A), 
en-tCDTA had a pH-dependent T1/T2 relaxivity increase from 
0.82/0.85  L·mmol−1·s−1 at pH 7.4 to 1.77/2.02  L·mmol−1·s−1 
at pH 5.1. In serum (Figure 6B), the T1/T2-relaxivity increase 
was threefold, from 0.72/0.75  L·mmol−1·s−1 at pH 7.4 to 
2.24/2.73 L·mmol−1·s−1 at pH 5.0. The sigmoidal dose response 
plots revealed a 50% pH of 6.79 ± 0.07/6.84 ± 0.07 (T1/T2) in 
water and a 50% pH of 6.17 ± 0.11/6.08 ± 0.09 in serum. Figure 
6C shows the pH-dependent T1 relaxivity of [Fe(en-tCDTA)]
+ 
at 7 T in serum, which was determined by MR imaging with TR 
variation on a 7 T Bruker small animal scanner.
The high linearity of the relaxivities of [Fe(en-tCDTA)]+ 
over the measured pH range suggests that they are not a 
function of [Fe(en-tCDTA)]+ concentration and thus of the 
ratio of [Fe(en-tCDTA)]+ to hydroxide ions (see Supporting 
Information Figure S6). A comparable pH dependence below 
pH7.4 was observed for the [Fe(en-Di-tCDTA)] dimer (see 
Supporting Information Figure S7B). The relaxivities of the iron 
complexes coupled with the rigid diamine [Fe(trans-tCDTA)]+ 
and [Fe(trans-Di-tCDTA)] (see Supporting Information Figure 
S7C,D) were also found to have decreasing relaxivities with 
increasing pH; however, in contrast to the ethylenediamine de-
rivatives, they exhibited this behavior above pH7.4.
4 |  DISCUSSION
Based on the promising results with IBCA, especially with 
[Fe(tCDTA)]−, as potential alternatives that can replace 
GBCA in contrast-enhanced T1-weighted MRI,
11 we aimed 
at modifying tCDTA to potentially further improve relax-
ivities and to generate iron chelates with different molecular 
properties for various clinical applications.
Using an efficient 2-step synthesis procedure, we created 
4 new tCDTA derivatives by reaction of 2 different diamine 
compounds in either an excess or less than half-molar ratio 
with tCDTA-MA, which was generated in the first reaction 
step. After having confirmed purity of the derivatives and es-
pecially the absence of the starting material, tCDTA, to rule 
out a contribution of [Fe(tCDTA)]− to subsequently mea-
sured relaxivities and having obtained proof of identity by 
MALDI mass spectrometry, NMR, and elemental analyses, 
we made several observations.
The iron complexes of the ethylenediamine derivatives 
en-tCDTA and en-Di-tCDTA had surprisingly low T1 and 
T2 relaxivities in comparison to tCDTA at neutral pH. It has 
been shown previously that the substantially lower relaxiv-
ity of the 7-coordinated [Fe(DTPA)]2- complex compared 
F I G U R E  4  Contrast effects of [Fe(trans-tCDTA)]+ and 
[Fe(trans-Di-tCDTA)] in T1-weighted MR imaging at 3 T. The   
images show spectrometer tubes containing 3 concentrations   
(1: 125 µM, 2: 250 µM, and 3: 500 µM Fe) of [Fe(trans-tCDTA)]+   
(A, B) or [Fe(trans-Di-tCDTA)] (C, D) in water or in 100% fetal 
bovine serum at neutral pH. (A, C) Signal intensity images acquired 
with a T1-weighted spin echo sequence at 3 T (TE 13 ms, TR 150 ms). 
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with the 6-coordinated [Fe(tCDTA)]− complex is due to 
the fact that in the latter a coordination site remains open 
for the coordination of water, which allows inner sphere 
relaxation.11,12 Analogously, the low relaxivities of [Fe(en-
tCDTA)]+ and [Fe(en-Di-tCDTA)] could be assumed to re-
sult from coordination of the terminal amine group in these 
compounds with the central iron(III), thereby preventing 
the water coordination and exchange with bulk water, 
which is required for the important inner-sphere relaxation. 
This hypothesis (Figure 5) is supported by the strong pH 
dependence of [Fe(en-tCDTA)]+ with a substantial re-
laxivity increase from neutral pH toward pH 5.0. At low 
pH, the terminal amine should become protonated, which 
would prevent coordination of the iron and thus leave 1 Fe 
coordination site available for water coordination (Figure 
5A). Interestingly, the pH levels at which half-maximal T1 
relaxivity occurred were approximately 6.8 in water and 
6.2 in serum, which might be explained by electron den-
sity reduction of the distal amine group by the amide group 
of the coupled ethylenediamine, thereby lowering the pKa 
of the amine. A similar mechanism might explain the rel-
atively low relaxivity and pH dependence of the [Fe(en-
Di-tCDTA)] dimer, where the 2 introduced amides of the 
ethylenediamine bridge possibly coordinate with the 2 
Fe(III) ions, thereby blocking inner-sphere water coordi-
nation and relaxation. Alternatively, the low relaxivities 
at neutral and higher pHs might be attributable to block-
age of the central iron by coordination of hydroxide ions 
at higher concentrations, which at the same time would 
prevent inner sphere relaxation (Figure 5C,E). In fact, 
[Fe(trans-tCDTA)]+ and [Fe(trans-Di-tCDTA)] with rigid 
diamines were also deactivated at higher pHs (Supporting 
Information Figure S7C,D) but above pH7.4. This pH de-
pendency may be attributed to increased contribution of 
F I G U R E  5  Hypothetical mechanisms of the observed pH-dependent relaxivity changes of [Fe(en-tCDTA)]+ and [Fe(trans-tCDTA)]+. (A) 
At slightly acidic pH, the terminal free amine group could be protonated, which in turn would prevent the iron coordination. Consequently, 1 
coordination site would be available for water coordination, allowing efficient inner sphere relaxation. (B) At neutral and high pH, the terminal 
amine group becomes deprotonated and thus could coordinate to central iron, block water coordination, and prevent efficient inner sphere 
relaxation. (C) At neutral and higher pH, higher concentrations of hydroxide ions can coordinate the central iron and thus block water coordination 
and inner sphere relaxation. (B) and (C) could coexist, but (C) seems more likely to occur at higher pHs. (D) The terminal free amine group of 
the rigid trans-1,4-diaminocyclohexane cannot coordinate the iron, which would explain the relatively high relaxivity at neutral and low pH 
(Supporting Information Figure S7). (E) At higher pH, high concentrations of hydroxide ions can coordinate to iron and thus block water access 
and reduce relaxivity. The pH-dependent relaxivities of the dimers [Fe(en-Di-tCDTA)] and [Fe(trans-Di-tCDTA)] could be explained accordingly 
to the correspondent monomers
(A) (B) (C)
(D) (E)
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the iron hydroxide complex as pH increases. Furthermore, 
[Fe(en-tCDTA)]+ relaxivities were independent of [Fe(en-
tCDTA)]+ concentration and thus the concentration ratio 
to hydroxide over the full pH range tested (see Supporting 
Information Figure S6). Therefore, we hypothesize in 
Figure 5 that the relaxivity decrease of [Fe(en-tCDTA)]+ 
with increasing pHs below pH7.4 is dominated by the coor-
dination of the distal amine, whereas for the 2 trans-1,4-di-
aminocyclohexane derivatives, the relaxivity decrease at 
higher pH is mainly attributable to hydroxide.
Because slightly lower extracellular pH levels are typical 
for many cancers,22,23 the pH-dependent T1 relaxivity in-
crease of [Fe(en-tCDTA)]+ might be exploited for the detec-
tion or characterization of cancer by MRI. Another important 
example for pH imaging is the identification of salvageable 
tissue in stroke.24,25 The low molecular weight complex 
should be superior to pH nanosensors26-29 in terms of a faster 
and broader biodistribution, including a more efficient ex-
cretion. The plain activation characteristic and relatively 
strong T1 relaxivity increase of [Fe(en-tCDTA)]
+ in compar-
ison to previously reported complex-based T1-relaxivity pH 
sensors30-33 could be advantageous and simplify MR image 
analysis in the future. Undeniably, clinical use of such pH 
sensor probes remains challenging because the T1 contrast 
effect depends on both relaxivity and local concentration. 
Nevertheless, probes such as [Fe(en-tCDTA)]+ can be very 
useful for preclinical research, for example, when adminis-
tered by Alzet osmotic pump to achieve constant blood con-
centrations as demonstrated by Savić et al.34
To produce always-on Fe complexes comparable to clin-
ically used GBCA, we chose trans-1,4-diaminocyclohexane 
as a more rigid amine linker molecule that should prevent 
the potential amine coordination and thus blockage of the 
important water coordination side. As predicted, the iron 
complexes of both the monomer trans-tCDTA and the dimer 
trans-Di-tCDTA were shown to have substantially higher re-
laxivities than their ethylenediamine counterparts at neutral 
pH (but not at high pH, see above), whereas their relaxivities 
were not much higher than those of [Fe(tCDTA)]− at 0.94 T.
Remarkably, T1 relaxivities of the iron complexes increased 
with higher magnetic field strengths. [Fe(trans-tCDTA)]+ and 
[Fe(trans-Di-tCDTA)] had especially high relaxivities at the 
typical clinical field strengths of 1.5 T and 3 T and still high 
relaxivities at 7 T. This is important, especially considering that 
the T1 relaxivities of 2 of the 3 macrocyclic GBCA products 
currently available clinically in Europe decrease with increasing 
field strengths.35 At 3 T, [Fe(trans-Di-tCDTA)] in blood serum 
has slightly higher T1 relaxivity per metal ion than gadoteridol 
(ProHance, Bracco Diagnostic S.p.S, Milan, Italy) and gadoter-
ate (Dotarem, Guerbet LLC, Paris, France) and slightly lower 
T1 relaxivity compared with gadobutrol (Gadovist, Bayer AG, 
Pharmaceuticals, Berlin, Germany) in blood plasma, whereas 
F I G U R E  6  MR imaging of pH-dependent contrast effects of [Fe(en-tCDTA)]+ at 1.5 T and 7 T. Seven spectrometer tubes containing either 
1 mM (A-D) or 3 mM (E-F) of [Fe(en-tCDTA)]+ in 100% fetal bovine serum with adjusted pHs between 5.8 and 7.4 were imaged with a T1-
weighted pulse sequence at magnetic field strengths of 1.5 T and 7 T. (A, E) Signal intensity images (spin echo sequence, TR 150 ms, TE 11 ms) 
and (B, F) corresponding T1 maps in seconds acquired in a clinical 1.5 T MRI scanner. (C, G) Signal intensity images (spin echo sequence,   
TR 71.8 ms, TE 9 ms) and corresponding T1 maps in milliseconds (D, H) obtained in a Bruker 7 T small animal MRI scanner. Imaging was 
performed at room temperature
(A) (B) (C) (D)
(E) (F) (G) (H)
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its T1 relaxivity per molecule is higher than that of all 3 of these 
products. Field strength-dependent T1 relaxivity peaked at 7 T 
for [Fe(tCDTA)]−, whereas it was highest at 3 T for [Fe(trans-
tCDTA)]+ and [Fe(trans-Di-tCDTA)]. The relaxivity increases 
in serum in comparison to water were slightly lower than for 
the mentioned macrocyclic GBCA in plasma, indicating a 
similar low plasma protein adsorption.36 Therefore, [Fe(trans-
tCDTA)]+ and [Fe(trans-Di-tCDTA)] might be potential alter-
natives to GBCA. Additionally, using the terminal amino group 
as linker, [Fe(trans-tCDTA)]+ could serve as an MRI-detectable 
label, for example, when coupled to specific imaging probes. 
Because specific probes principally bind to tissue structures, 
delayed excretion and gadolinium depositions would become 
even more likely when GBCA would be used for such imaging 
probes.
Importantly, the very high stability of [Fe(tCDTA)]−20 was 
not substantially reduced by our modifications of tCDTA. In 
fact, like tCDTA, all new tCDTA derivatives resisted the chal-
lenge with 100 mM HCl for 72 h, which was not the case for 
the macrocyclic iron complexes presented by Snyder et al.14 
We observed a small change in absorption during the first 
hour, which we attribute to protonation of the chelating amines 
of tCDTA and thus cleavage of the respective coordinative 
bonds. The rapid time course of this small absorption change 
for [Fe(trans-Di-tCDTA)] is shown in Supporting Information 
Figure S5. However, the iron complexes appeared to retain 
their stability with the 4 remaining coordinating oxygens. This 
might also explain, based on the hard and soft acids and bas-
es-principle—hard acid Fe(III) and hard base O—the lower 
stability of the macrocyclic chelators of Snyder et al., which 
coordinate with 3 or 4 amines but only with 2 oxygens.14
Electrochemical data suggest that the [Fe(tCDTA)]− com-
plex is not prone to iron redox cycling and thus ROS-induced 
toxicity under physiological conditions. Merkofer et al. had 
reported an ascorbyl/monohydroascorbate physiological elec-
trode potential of approx. +0.1 V versus NHE (corresponding 
to −0.1 V vs. Ag/AgCl,37 which means that “unproblematic” 
Fe(III) complexes should show electrode potentials lower 
than −0.1 V. [Fe(tCDTA)]− (Ec= −0.16 V vs. Ag/AgCl), 
which is well below this value, whereas the other complexes 
are at least close with Ec ≈ 0 V. However, it should be noted 
that, for the presented cyclic voltammetry measurements, 
conditions are not completely matching physiological con-
ditions such as micromolar concentrations of the complexes 
F I G U R E  7  [Fe(en-tCDTA)]+ is a pH 
sensor. (A) pH dependence of T1 and T2 
relaxivity of [Fe(en-tCDTA)]+ in water at 
0.94 T. (B) pH dependence of T1 and T2 
relaxivity of [Fe(en-tCDTA)]+ in serum at 
0.94 T. (B) pH dependence of T1 and T2 
relaxivities of [Fe(en-tCDTA)]+ in serum 
at 7 T. Curves represent the sigmoidal 
dose-response fits with 95% confidence 
bands (dotted lines). (A, B) Relaxivities 
determined with a relaxometer, (C) T1 
values calculated from MR imaging 
performed in a 7 T Bruker scanner with 
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and pH 7.37 It is to be expected that even more negative elec-
trode potentials would result12 at higher pH values than the 
value applied here (pH 5.9). The fact that we observed 2 
cathodic peak potentials for the [Fe(trans-Di-tCDTA)] com-
plex and [Fe(en-tCDTA)]+ might originate from 2 different 
reasons: the presence of different metal-bound species like 
Fe-OH2 and Fe-OH (the aqua form is reduced more readily 
than the hydroxide form12) and/or, in the case of [Fe(trans-
Di-tCDTA)], slightly different potentials for the 2 Fe(III) 
centers. Future studies will be necessary to thoroughly inves-
tigate redox activities under physiological conditions.
Although thermodynamically possible, it is unclear to 
what degree this redox cycling will occur in blood and other 
fluids comprising the extracellular spaces. These complexes 
likely distribute through the extracellular spaces and should 
be very rapidly and efficiently excreted, suggesting that, even 
if redox cycling does occur, it is unclear whether transient 
exposure will lead to any toxic effect.
5 |  CONCLUSION
Straightforward 2-step synthesis allowed the generation of 
2 derivatives of [Fe(tCDTA)]−, [Fe(trans-tCDTA)]+ and 
[Fe(trans-Di-tCDTA)] with improved relaxivities while pre-
serving high stability compared with [Fe(tCDTA)]−. These 
new IBCA have favorable relaxivities at 1.5, 3, and 7 T that 
are in the range of clinically available GBCA. A third deriva-
tive, [Fe(en-tCDTA)]+, provides pH sensing capability and is 
activated at weakly acidic pH, making it a potential candidate 
for better MRI-based characterization of cancer tissues or tis-
sue at risk in stroke by MRI.
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FIGURE S1 HPLC
FIGURE S2 MALDI Mass spectrometry
FIGURE S3 Infrared spectroscopy
FIGURE S4 Nuclear magnetic resonance analysis
FIGURE S5 Absorbance change of [Fe(trans-Di-tCDTA)] in 
100 mM HCl during first hour. (A) Corresponding to figure 
2, a small change of the absorption spectrum of [Fe(trans-
Di-tCDTA)] was recorded during first hour (interval 2 min) 
after diluting in 100 mM HCl. (B) Time-course of absorp-
tion at 300 nm. The rapid change (exponential decay, K = 
0.130 ± 0.007) during the first minutes might be explained 
by protonation of the chelating amines and thus cleavage of 
the respective coordinative bonds (but maintaining stability 
through coordinative oxygen bonds, Figure 2)
FIGURE S6 Relaxivity determination of Fe[en-tCDTA]+ 
calculated from relaxometer measurements at 0.94T. x-axis: 
Fe[en-tCDTA]+ concentrations [mM] iron; y-axis: 1/T1 in 
[1/s]
FIGURE S7 Comparison of the pH-dependent relaxivi-
ties of the iron(III)-tCDTA derivates coupled with flexible 
ethylenediamine (en) versus rigid trans-1,4-diaminoclyclo-
hexane (trans). (A) [Fe(en-tCDTA)]+ monomer, (B) [Fe(en-
Di-tCDTA)] dimer, (C) [Fe(trans-tCDTA)]+ monomer, and 
(D) [Fe(trans-Di-tCDTA)] dimer. The relaxivity decrease 
occurred for the en derivates below pH7.4 and for the trans 
derivatives above pH 7.4. Relaxivities were measured on a 
relaxometer at 0.94T and 37°C in water
TABLE S1 Cyclic voltammetry. Cathodic, anodic and half-
wave potentials of iron-complexes
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